Fluoguide AS
STO:FLUO
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
33.9
75.6
|
Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Fluoguide AS
Other Current Assets
Fluoguide AS
Other Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Other Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
F
|
Fluoguide AS
STO:FLUO
|
Other Current Assets
kr180k
|
CAGR 3-Years
0%
|
CAGR 5-Years
61%
|
CAGR 10-Years
N/A
|
|
Genmab A/S
CSE:GMAB
|
Other Current Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Zealand Pharma A/S
CSE:ZEAL
|
Other Current Assets
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
||
Ascendis Pharma A/S
NASDAQ:ASND
|
Other Current Assets
€32.4m
|
CAGR 3-Years
13%
|
CAGR 5-Years
33%
|
CAGR 10-Years
45%
|
||
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Other Current Assets
kr59m
|
CAGR 3-Years
21%
|
CAGR 5-Years
10%
|
CAGR 10-Years
13%
|
|
Bioporto A/S
CSE:BIOPOR
|
Other Current Assets
kr2.3m
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
Fluoguide AS
Glance View
FluoGuide A/S engages in the development of surgical solutions to reduce suffering for the patient and increase the likelihood of cure; as well as reducing costs for the health care system. The firm develops surgical solutions, which expected to reduce Cancer pain for the patient and increases the possibility of recovering as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue.
See Also
What is Fluoguide AS's Other Current Assets?
Other Current Assets
180k
DKK
Based on the financial report for Dec 31, 2023, Fluoguide AS's Other Current Assets amounts to 180k DKK.
What is Fluoguide AS's Other Current Assets growth rate?
Other Current Assets CAGR 5Y
61%
Over the last year, the Other Current Assets growth was 1 025%.